Pálka István, Kelemen Gyöngyi, Ormándi Katalin, Lázár György, Nyári Tibor, Thurzó László, Kahán Zsuzsanna
Department of Pathology, University of Szeged, Szeged, Hungary.
Pathol Oncol Res. 2008 Jun;14(2):161-7. doi: 10.1007/s12253-008-9010-7. Epub 2008 Mar 6.
The natural course of early breast cancer has changed as a result of the introduction of mammographic screening. The present aim was a prospective analysis of screen-detected and symptomatic operable breast cancers in the era of mammographic service screening. The mode of detection (screen-detected, symptomatic or interval cancer), the type of mammographic image and other characteristics (the invasive tumor size, histological tumor type, grade, nodal, hormone receptor and HER2 status and the presence of lymphovascular invasion) of 569 invasive breast cancers were studied. Screen-detected cancers were significantly more frequently of grade I, < 10 mm of size and node-negative (p < 0.001, respectively). Symptomatic/interval cancers were significantly more frequently of grade 3, >20 mm of size (p < 0.001), and exhibited lymphovascular invasion (p = 0.001). Screening-detection of the tumor favored breast-conserving surgery, sentinel lymph node biopsy and the avoidance of chemotherapy (p < 0.001). Cancers associated with casting-type calcifications on the mammogram were typically of ductal type (p = 0.043), of grade 2-3, estrogen receptor and progesterone receptor-negative and HER2-positive (p < 0.001). Interval cancers occurred significantly more often at a younger age and remained mammographically occult as compared with other cancers. Mammographic screen-detected cancers demonstrate more favorable prognostic features, and need less extensive treatment than symptomatic or interval cancers. The mammographic appearance of the tumor reflects its biological behavior, and this should be considered in the management optimization.
由于乳腺钼靶筛查的引入,早期乳腺癌的自然病程发生了改变。当前的目的是对乳腺钼靶服务筛查时代经筛查发现和有症状的可手术乳腺癌进行前瞻性分析。研究了569例浸润性乳腺癌的检测方式(筛查发现、有症状或间期癌)、乳腺钼靶图像类型及其他特征(浸润性肿瘤大小、组织学肿瘤类型、分级、淋巴结、激素受体和HER2状态以及是否存在淋巴管浸润)。经筛查发现的癌症I级、大小<10mm且无淋巴结转移的情况明显更为常见(p值分别<0.001)。有症状/间期癌3级、大小>20mm的情况明显更为常见(p<0.001),且表现出淋巴管浸润(p = 0.001)。肿瘤的筛查发现有利于保乳手术、前哨淋巴结活检及避免化疗(p<0.001)。乳腺钼靶上与铸型钙化相关的癌症通常为导管型(p = 0.043),2 - 3级,雌激素受体和孕激素受体阴性且HER2阳性(p<0.001)。与其他癌症相比,间期癌在更年轻的年龄出现的频率明显更高,且在乳腺钼靶上仍为隐匿性。经乳腺钼靶筛查发现的癌症显示出更有利的预后特征,与有症状或间期癌相比,所需的治疗范围更小。肿瘤的乳腺钼靶表现反映了其生物学行为,在优化治疗管理时应予以考虑。